
French pharmaceutical company Servier Laboratories and biotech company Neurochlore have stopped clinical trials of Bumetanide on autistic children.
In 2017, Servier and Neurochlore joined forces to accelerate the development and marketing of a treatment called Bumetanide on autistic people in Europe.
Servier was responsible for the marketing of the product in Europe, whilst the biotech company retained the licensing rights for use in the United States.
Professor Ben-Ari, who had been studying bumetanide for a number of years, published research in Science magazine in 2014, claiming that ‘autistic behaviours can be prevented’ in female offspring before before.
But after four years of studies, in 14 different countries, the two double-blind randomized studies versus a placebo have been abandoned as results of the bumetanide drug against the placebo were not effective.
Servier and Neurochlore have both agreed to terminate the two clinical studies in Europe and the United States.
It was the largest clinical trials across Europe that reached Phase 3 clinical trials, that was dedicated to finding the bogus “cure” in to autism.
Autistic people and advocates will rejoice at this kind of news, who have been campaigning for decades to re-educate scientists that autism is not a disease that needs treating.
Full joint-statement by Servier and Neurochlore
Servier and Neurochlore announce that no sign of effectiveness was observed in their two phase 3 clinical studies assessing bumetanide versus placebo in the treatment of Autism Spectrum Disorders (ASD) in children and adolescents. As a consequence, Servier and Neurochlore have decided, by mutual agreement, on an early termination of the two clinical studies in progress.
These two double-blind randomized phase 3 studies versus placebo were initiated 4 years ago in 14 countries, including 11 in Europe, within the framework of the Pediatric Investigation Plan (PIP) granted by the European Agency of Medicine (EMA). Thus, 422 children and adolescents with moderate-to-severe ASD, shared between the two studies, each with 211 participants according to their age (2-6 years and 7-17 years), were followed over 6 months in a double-blind placebo-controlled study, before being followed on bumetanide for an additional 6 months. It is the largest phase 3 European program dedicated to the treatment of core symptoms of autism in pediatrics.
The results of these studies haven’t demonstrated the superiority of bumetanide compared with placebo. None of the effectiveness criteria, both primary (CARS – Childhood Autism Rating Scale) and secondary (SRS – Social Responsiveness Scale -, CGI Scale – Clinical Global Impression Scale -, Vineland) were reached after 6 months of treatment, not in children aged 2-6 years or in children and adolescents aged 7-17 years. The studies didn’t reveal any unexpected safety issue associated with the use of bumetanide.
These two phase 3 studies conducted by Servier followed a phase 2B trial sponsored by Neurochlore which was carried out in 6 centers in France in 90 autistic children and adolescents. The encouraging results from this clinical trial led to a partnership agreement between Servier and Neurochlore that was signed in March 2017, with the objective of developing bumetanide as the first treatment for ASD in children and adolescents.
“We had high hopes for bumetanide, which had shown the potential to improve the core symptoms of children and adolescents with autism and the quality of life of their families. We are even more disappointed that today no pharmacological treatment exists to help these young children,” explains Claude Bertrand, Executive Vice President R&D of Servier. “We are pleased to have collaborated with Neurochlore on the development of bumetanide in the core symptoms of autism. This study program was carried out in an extremely rigorous manner, according to the highest standards of quality. We would like to thank the participating families, as well as the investigators and the centers for their involvement in the realization of these clinical studies.”
“The results of the phase 3 clinical studies are a major disappointment,” declares Professor Yehezkel Ben-Ari, President of Neurochlore. “Neurochlore’s teams will now analyze in detail the results of the studies and potentially explore new approaches based on artificial intelligence, which may enable us to identify sub-populations of people suffering from Autism Spectrum Disorders, for whom bumetanide could be effective.
The heterogeneity of ASDs probably makes it impossible to offer a sole treatment for all autistic children. We are proud of the work accomplished by the teams who conducted these studies. We would like to thank the children and their families who participated in the trials and for whom the medical need remains significant.”